QuantX Biosciences closed an $85 million Series B led by Lilly and Sanofi Ventures to advance an immunology pipeline developed across China and the U.S. The round supports QuantX’s AI‑driven discovery of biologics targeting established immune pathways. The financing underscores continuing strategic investments by pharma venture arms into computationally driven biotech startups, and it gives QuantX both capital and potential developmental partners as it advances candidates through IND enabling work and early clinical milestones.